Investigational drug · Phase 2
Samuraciclib
Also called: ICEC0942, CT7001
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
7
Any phase or sponsor naming "Samuraciclib"
First trial start
2021
Jun 22, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Samuraciclib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Breast Cancer
- Locally Advanced Breast Cancer
- Breast Cancer
- Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Samuraciclib" as an intervention, largest first.
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04802759 · 316 participants (planned) · Start Jun 22, 2021 · Primary completion May 30, 2029
Drug: Giredestrant; Abemaciclib and 8 more · For: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Sites: Duarte, California; Irvine, California; San Francisco, California · 32 sites in all
- Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced MalignanciesPivotal-lookingCompleted
Carrick Therapeutics LimitedIndustry
NCT03363893 · 124 participants · Start Nov 14, 2017 · Primary completion Dec 15, 2022
Drug: CT7001; Fulvestrant · For: Advanced Solid Malignancies
Sites: Tucson, Arizona; Beverly Hills, California; Tampa, Florida · 23 sites in all
- Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic CancerNot yet recruiting
University Health Network, TorontoAcademic, hospital or other
NCT07665684 · 67 participants (planned) · Start Jul 2026 · Primary completion May 2029
Drug: Samuraciclib + Gemcitabine & Nab-Paclitaxel · For: Pancreas Ductal Adenocarcinoma; Pancreas Cancer, Metastatic; Pancreatic Adenocarcinoma Metastatic and 2 more
Sites: Toronto, Canada
Carrick Therapeutics LimitedIndustry
NCT05963984 · 60 participants · Start Nov 16, 2023 · Primary completion Mar 20, 2025
Drug: Samuraciclib; Fulvestrant · For: Metastatic Breast Cancer; Locally Advanced Breast Cancer; Breast Cancer
Sites: Ocala, Florida; Baltimore, Maryland; Kansas City, Missouri · 32 sites in all
Carrick Therapeutics LimitedIndustry
NCT05963997 · 49 participants · Start Oct 9, 2023 · Primary completion Mar 6, 2026
Drug: Samuraciclib; Elacestrant Dihydrochloride · For: Metastatic Breast Cancer; Locally Advanced Breast Cancer; Breast Cancer
Sites: Chicago, Illinois; Boston, Massachusetts; Cleveland, Ohio · 23 sites in all
University of WashingtonAcademic, hospital or other
NCT07645651 · 15 participants (planned) · Start Dec 1, 2026 · Primary completion Jul 14, 2027
Drug: Samuraciclib · For: Resectable Pancreatic Ductal Adenocarcinoma; Borderline Resectable Pancreatic Ductal Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma
Sites: Seattle, Washington
PfizerPfizer (PFE)
NCT06125522 · 11 participants · Start Jan 10, 2024 · Primary completion Sep 10, 2026
Drug: vepdegestrant; Samuraciclib · For: Breast Cancer
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Functional insight into cyclin-dependent kinase (CDK)7 via chemical inhibition of the priority fungal pathogen Cryptococcus neoformans.
Sethiya P, Desmarini D, Bowring BG, et al. · mBio 2025
- CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer.
Otero-Rosales M, Álvarez-González M, Pazos I, et al. · Signal Transduct Target Ther 2025
- Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells.
Lai CF, Cushing VI, Olden E, et al. · EMBO J 2025
- Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC, Howell S, Lord SR, et al. · Nat Commun 2025
- Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Constantin TA, Varela-Carver A, Greenland KK, et al. · Br J Cancer 2024
- Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition.
Wilson GA, Vuina K, Sava G, et al. · Mol Cell 2023
Also in development for Metastatic Breast Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- LasofoxifeneAZU-101Phase 34 trials
Sermonix Pharmaceuticals Inc. · Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.